Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10 microgram recombinant hepatitis B vaccine plus different HBIG doses for prevention of mother-to-child HBV transmission
ChiCTR-PRC-12002791Phase 4Completed
- Sponsor
- Chinese Center for Disease Control and Prevention
- Start
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Hepatitis B vaccine and hepatitis B immune globulin in hepatitis B (HBV) (2 arms), sponsored by Chinese Center for Disease Control and Prevention. Primary endpoints: HBsAg, anti-HBs and 4 more. Started Jan 2012; status: completed.
02
Drugs
Hepatitis B vaccinehepatitis B immune globulin
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR-PRC-12002791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-PRC-12002791.